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BACKGROUND: p53 is the most commonly mutated tumour-suppressor gene in human cancers. Unlike other tumour-suppressor
genes, most p53 cancer mutations are missense mutations within the core domain, leading to the expression of a full-length mutant
p53 protein. Accumulating evidence has indicated that p53 cancer mutants not only lose tumour suppression activity but also gain
new oncogenic activities to promote tumourigenesis.
METHODS: The endogenous mutant p53 function in human breast cancer cells was studied using RNA interference (RNAi). Gene
knockdown was confirmed by quantitative PCR and western blotting. Apoptosis was evaluated by morphological changes of cells,
their PARP cleavage and annexin V staining.
RESULTS: We show that cancer-associated p53 missense mutants are required for the survival of breast cancer cells. Inhibition of
endogenous mutant p53 by RNAi led to massive apoptosis in two mutant p53-expressing cell lines, T47D and MDA-MB-468, but not
in the wild-type p53-expressing cells, MCF-7 and MCF-10A. Reconstitution of an RNAi-insensitive mutant p53 in MDA-MB-468 cells
completely abolished the apoptotic effects after silencing of endogenous mutant p53, suggesting the specific survival effects of mutant
p53. The apoptotic effect induced by mutant p53 ablation, however, is independent of p63 or p73 function.
CONCLUSION: These findings provide clear evidence of a pro-survival ‘gain-of-function’ property of a subset of p53 cancer mutants in
breast cancer cells.
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p53 is the most extensively studied tumour-suppressor gene,
encoding a sequence-specific transcriptional regulator that con-
trols a plethora of biological functions, including cell-cycle
progression, senescence, differentiation, DNA repair, and apopto-
sis (Vogelstein et al, 2000; Oren, 2001, 2003). Under normal
conditions, p53 is maintained at low levels through targeted
degradation mediated by the human murine double minute 2
protein. In response to cellular stresses, such as oncogene
activation, DNA damage, and hypoxia, p53 activity increases to
exert its function as a transcription factor, resulting in a cascade of
events that eventually prevent tumour development (Lowe and
Ruley, 1993; Nelson and Kastan, 1994; Graeber et al, 1996).
Given pivotal function of p53 in tumour suppression, it is no
surprise that the p53 gene is the most frequent target for genetic
alterations in human cancers (Hollstein et al, 1996). However,
unlike other tumour-suppressor genes that are typically deleted,
truncated, silenced, or otherwise downregulated, the majority of
p53 alterations are missense mutations in the DNA-binding
domain, often leading to a high constitutive expression of mutant
p53 in tumour cells (Sigal and Rotter, 2000). Although these
frequent p53 mutations serve primarily to abrogate the tumour-
suppressor function of wild-type p53, there is growing evidence
that the resultant mutant p53 proteins may also contribute actively
to tumourigenesis through either a dominant-negative or a gain-
of-function mechanism (Sigal and Rotter, 2000; Cadwell and
Zambetti, 2001; Zalcenstein et al, 2003; Kim and Deppert, 2004).
The dominant-negative effect of mutant p53 is strongly supported
by the observation that mutant p53 proteins oligomerise with wild-
type p53 and inhibit its function (Milner and Medcalf, 1991; Milner
et al, 1991; Willis et al, 2004). The ‘gain-of-function’ theory, on the
other hand, suggests that p53 mutations actively promote
tumourigenesis, independent of the loss of wild-type p53 function.
The notion for the mutant p53 gain-of-function theory is supported
by recent studies using mutant p53 ‘knockin’ mice, which display a
broader tumour spectrum, increased aggressiveness, and metastatic
potential as compared with their p53-null counterparts (Hsiao et al,
1994; Liu et al, 2000; Lang et al, 2004; Olive et al, 2004). In cultured
cells, overexpression of tumour-associated p53 mutants was also
shown to interfere with stress-induced apoptosis, increase resistance
to chemotherapeutic drugs (Lotem and Sachs, 1995; Li et al, 1998;
Blandino et al, 1999; Matas et al, 2001; Bergamaschi et al, 2003),
promote genomic instability (Murphy et al, 2000), and enhance
proliferation (Aas et al, 1996; Blandino et al,1 9 9 9 ) .S e v e r a l
biochemical and biological functions of mutant p53 proteins,
independent of the wild-type p53 protein, have also been described.
For instance, the mutant p53 protein was shown to be an activator of
numerous genes, such as c-Myc, topoisomerase I,a n dMDR-1
(Murphy et al, 2000), and to promote genomic instability and
disruption of spindle checkpoint control (Matas et al, 2001).
Although in vivo experiments provided validation for the gain-of-
function properties of certain p53 missense mutants, they are limited
in their usefulness as a specific model for studying mutant p53
function in human breast cancer, because these mice rarely if ever
develop breast cancer. In contrast, breast cancer is the most common
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scancer observed in patients with the Li-Fraunmeni syndrome
inheriting the analogous p53 mutations (Olivier et al, 2003).
Using the RNA interference (RNAi) approach, we investigated
the functional task of mutant p53 in human breast cancer cells. We
show that silencing of mutant p53 in T47D and MDA-MB-468 cells
induced massive apoptosis. Although one postulated mechanism
for a dominant effect of mutant p53 is through the inhibition of
p63 and/or p73 (Di Como et al, 1999; Strano et al, 2000; Gaiddon
et al, 2001), the apoptosis induced by mutant p53 knockdown in
breast cancer cells is independent of the p63 or p73 function. As
both T47D and MDA-MB-468 cells express only mutant p53, our
findings also show that the effect we observe is not because of the
dominant-negative function of mutant p53 towards wild-type p53.
Taken together, these findings suggest a function for mutant p53 in
mediating the survival of human breast cancer cells.
MATERIALS AND METHODS
Cell lines and plasmids
Human breast carcinoma cell lines MCF-7, MDA-MB-468, and T47D
were maintained in RPMI 1640 containing 10% FBS, 100IUml
 1
penicillin, and 100mgml
 1 streptomycin (Sigma-Aldrich, St Louis, MO,
CA, USA). MCF-10A cells were grown in DMEM-F12 (Invitrogen,
Carlsbad, CA, USA), supplemented with 5% horse serum, 20ngml
 1
EGF, 0.5mgml
 1 hydrocortisone, 100ngml
 1 cholera toxin, 10mgml
 1
insulin, 100IUml
 1 penicillin, and 100mgml
 1 streptomycin.
Lentiviral production and infection
The small-hairpin RNA (shRNA) lentiviral constructs were created
by transferring a U6 promoter-shRNA cassette into a lentiviral
backbone, and high-titre lentiviral stocks were generated by co-
transfection with packaging vectors into 293T cells as described
previously (Rocco et al, 2006; Leong et al, 2007). Small-hairpin
RNA and siRNA target sequences were as follows: p53si-1,
50-CACCATCCACTACAACTACAT-30; p53si-2, 50-CGGCGCACAG
AGGAAGAGAAT-30; p53si-3, 50-AAAAGTCTAGAGCCACCG-30;
TAp63si, 50-GGGATTTTCTGGAACAGCCTAT-30; TAp73, 50-GGA
TTCCAGCATGGACGTCTT-30. The TAp73 targeted sequence is
found within p73 exon 3. Therefore, this shRNA does not target
DNp73 (Leong et al, 2007).
QRT-PCR analysis
Total RNA from cells was extracted using a Qiagen RNA isolation
kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocol. First-strand cDNA was synthesised from total RNA using
random hexamer primers and the SuperScript II system for
RT–PCR (Invitrogen). Gene expression levels were measured by
quantitative real-time PCR (QRT-PCR) using the iQ SYBR Green
Supermix reagent and an Bio-Rad iQ5 real-time PCR detector
system (Bio-Rad, Richmond, CA, USA). Data analysis was
performed using Bio-Rad 125 Optical System Software V1.0. The
expression of each gene was normalised to GAPDH or b2M as a
reference. Relative copy numbers were calculated from an 8-point
standard curve generated from a 10-fold serial dilution of full-
length cDNA constructs as described previously (Leong et al,
2007). Specific forward and reverse primer sequences are as
follows: p53fwd, 50-CCTCACCATCATCACACTGG-30; p53rev,
50-GCTCTCGGAACATCTCGAAG-30;p 7 3 f w d ,5 0-GCGACCGAAAAGC
TGATGAG-30; p73rev, 50-CGTGGCCATGGTTGTGGAG-30; p63fwd,
50-GGAAAACAATGCCCAGACTC-30; p63rev, 50-GTGGAATACGTC
CAGGTGGC-30; TAp73fwd, 50-GCACCACGTTTGAGCACCTCT-30;
TAp73rev, 50-GCAGATTGAACTGGGCCATGA-30; TAp63fwd, 50-A
AGATGGTGCGACAAACAAG-30; TAp63rev, 50-AGAGAGCATCG
AAGGTGGAG-30; B2Mfwd, 50-AGCTGTGCTCGCGCTACTCTC-30;
B2Mrev, 50-CACACGGCAGGCATACTCATC-30; GAPDHfwd, 50-CA
CCCAGAAGACTGTGGATGG-30; GAPDHrev, 50-GTCTACATGGC
AACTGTGAGG-30. The conditions for all QRT-PCR reactions were
as follows: 3min at 941C followed by 40s at 941C, 40s at 601C, and
25s at 721C for 40 cycles. All PCR products were confirmed by the
presence of a single peak upon melting curve analysis and by gel
electrophoresis. No-template (water) reaction mixtures and no-RT
mixtures were used on all samples as negative controls. All
experiments were performed in duplicate.
Apoptosis assays
Quantitation of apoptosis by annexin V/PI staining was performed
as described previously (Rocco et al, 2006). Briefly, both floating
and attached cells were collected 72h after p53-directed shRNA
lentiviral infection. Apoptotic cell death was determined using the
BD ApoAlert Annexin V–FITC Apoptosis Kit (BD Biosciences,
USA) according to the manufacturer’s instructions, and cells were
analysed on a FACSCalibur flow cytometer using CellQuest Pro
software (version 5.1.1; BD Biosciences, San Jose, CA, USA).
Protein isolation and western blot analysis
Protein lysates from cells were extracted in ice-cold lysis buffer
(0.75% NP-40, 1mM DTT, and protease inhibitors in PBS). Total
protein (25mg) was subjected to SDS–PAGE, followed by immuno-
blotting with the following antibodies: mouse monoclonal p53
(diluted 1:1000, DO-1; Santa Cruz Biotechnology, Santa Cruz, CA,
USA); p73 (diluted 1:1000, Ab-2; Calbiochem, San Diego, CA,
USA); poly(ADP-ribose) polymerise-1 (PARP; diluted 1:1000;
Cell Signaling Technology, Beverly, MA, USA); PUMA (diluted
1:1000, Ab9645; Abcam, Cambridge, MA, USA); b-tubulin
(diluted 1:2500, D-10; Santa Cruz Biotechnology); and NOXA
(diluted 1:1000, Ab13654; Abcam).
RESULTS
High expression of mutant p53 in T47D and MDA-MB-468
cells
Basal levels of the p53 protein were determined from exponentially
growing cells by western blotting, using DO-1 antibody. This
antibody recognises an epitope that resides between amino acids 11
and 25 of the p53 protein, and recognises both wild-type and mutant
p53. Cell lines that harbour a p53 missense mutation (T47D and
MDA-MB-468) showed a high level of p53 protein expression,
whereas only a low level of p53 protein product was detected in cells
that expressed wild-type p53 (MCF-10A and MCF-7) (Figure 1A).
We then compared the level of p53 mRNA expression in these breast
carcinoma cells with that observed in the non-transformed
myoepithelial cell line, MCF-10, using QRT-PCR. As a control, we
also examined p53 expression in the human osteosarcoma-derived
line Saos-2, which is reported not to express p53. As expected, no
protein product or mRNA expression was detected in this line
(Figures 1A and B). Our results show that all cell lines tested express
a similar level of p53 mRNA, consistent with a previous study that
showed that p53 missense mutants in T47D and MDA-MB-468 are
stabilised mutants (Mihara et al, 2003; Figure 1B).
Specific knockdown of p53 by shRNA
Next, we performed shRNA-mediated knockdown of mutant p53
in T47D and MDA-MB-468 cells, both of which express
endogenous mutant p53. We showed that two independent,
lentivirally expressed shRNA species exhibit at least 80% knock-
down of endogenous mutant p53 protein and message in T47D
cells, as assessed by real-time QRT-PCR and by western analysis
(Figure 1C), respectively. Importantly, none of these shRNAs
inhibit the expression of the other two closely related family
members, p63 or p73 (Figure 1C). The efficacy of the two
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sp53-directed shRNA species for p53 knockdown is comparable,
whereas infection with a control vector or a non-specific shRNA
does not affect endogenous p53 protein or message levels
(Supplementary Figure 1). This high infection efficiency allowed
us to carry out subsequent experiments on lentivirally infected cell
populations in the absence of drug or other selections to directly
evaluate the function of endogenous mutant p53 in breast
cancer cells.
Requirement of mutant p53 for survival in breast cancer
cells
We next examined the impact of silencing mutant p53 in both
T47D and MDA-MB-468 breast cancer cells. Both cell lines
have been reported to express only mutant p53 and not
wild-type p53 (IARC p53 database (http://www.iarc.fr/p53/
index.html)), and we confirmed this finding by direct cDNA
sequencing, which showed no wild-type p53 (data not
shown). Silencing of endogenous mutant p53 by lentiviral shRNA
in T47D and MDA-MB-468 cells induced massive cell death
associated with nuclear blebbing, PARP-1 cleavage, and annexin
V/PI staining, all hallmarks of apoptosis (Figures 2A–C). These
apoptotic effects, however, were not observed in MCF-7 or MCF-
10A cells (Figure 2, data not shown) that express only wild-type
p53, nor were they observed in T47D or MDA-MB-468 cells
transduced with a non-targeting shRNA. Thus, specific inhibition
of mutant p53 triggers apoptotic cell death in tumour cells in
which it is expressed.
Rescue of apoptosis by exogenous mutant p53
To further support the specific effect of p53 knockdown, we
established a gene replacement strategy to examine the ability of
exogenous mutant p53 to rescue the effects of endogenous mutant
p53 knockdown. An R273H mutant p53 expression construct
lacking the 50-untranslated region (50-UTR) of endogenous mRNA
was stably expressed in MDA-MB-468 cells. Pools of cells were
used to avoid clonal selection effects. As an initial test of this
reconstitution assay, cells stably expressing 50-UTR-deleted R273H
mutant p53 were transfected with an siRNA species targeting the
50-UTR (p53si-3) of the endogenous p53 mRNA. At 72h after
transfection, endogenous mutant p53 protein levels were virtually
undetectable in control vector-expressing cells (Figure 3A, lanes 1
vs 2). However, ectopic mutant p53 protein remained in p53
R273H-reconstituted cells (lanes 3 vs 4). The reconstituted cells
also showed dramatically less apoptosis as evidenced by annexin
V/PI staining, as well as a suppression of PARP-1 cleavage after
siRNA treatment (Figures 3A and B). Together, these controls
validated the idea that the apoptotic effects induced by the
knockdown of mutant p53 are indeed caused by the specific
inhibition of mutant p53 function. Thus, endogenous mutant p53
is critical for the survival of breast cancer cells.
Apoptosis after mutant p53 inhibition is independent of
endogenous p63 or p73
To begin to elucidate the mechanism of mutant p53 in breast
cancer cells, we assayed the expression of proapoptotic genes that
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Figure 1 High expression of stabilised mutant p53 in T47D and MDA-MB-468 cells. (A) Expression of endogenous p53 protein in a panel of human
breast cancer cell lines. Cell lysates were harvested from exponentially growing cells. Total protein (25mg) was subjected to SDS–PAGE, followed by
immunoblotting with mouse monoclonal DO-1 antibody that recognised both wild-type and mutant p53. Immunoblot for b-tubulin was used as loading
control. (B) p53 mRNA levels were similar in all cell lines, suggesting that the high level of p53 protein expressed in T47D and MDA-MB-468 is due to a
stabilisation of the mutant protein. (C) Specific knockdown of p53 using lentiviral shRNA. T47D cells were infected with a lentiviral supernatant in the
presence of 7.5mgml
 1 polybrene for 6h. The cells were then washed and replaced with fresh medium. p53 expression was determined by QRT-PCR and
immunoblotting 48 and 72h after infection, respectively. Note that either of the p53-specific shRNAs efficiently knocks down the expression of p53 but
does not knock down the other two family members, p63 and p73.
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Figure 2 Knockdown of endogenous mutant p53 induced apoptosis in breast cancer cells. (A) Apoptotic morphology after lentiviral p53 knockdown in
mutant p53-expressing cells, T47D and MDA-MB-468, but not in MCF-7 cells that express wild-type p53. Photomicrographs were taken 96h after lentiviral
shRNA infection. Original magnification,  100. (B) Knockdown of endogenous mutant p53 induced PARP-1 cleavage, as assessed by immunoblot of the
indicated cells 72h after infection with lentiviral shRNA vectors targeting two distinct p53 sequences (p53si-1 and p53si-2). None of these effects were
observed in MCF-7 cells that express wild-type p53, nor in T47D or MDA-MB-468 cells that were infected with control vector or a non-specific sequence
(NS). (C) Apoptosis was observed after endogenous mutant p53 knockdown, as assessed by annexin V/PI staining of unfixed cells 96h after infection with
the indicated lentiviral shRNA vectors. Percentages indicate apoptotic cells (annexin V positive and/or PI positive). Shown are results of annexin V/PI staining
for three independent experiments. Error bars represent s.d.
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sare known to be regulated by p53 and its family members.
Surprisingly, we did not observe any changes in the level of
expression of two potent pro-apoptotic proteins, PUMA and
NOXA, in either T47D (Figure 4A) or MDA-MB-468 cells (data not
shown) after knockdown of mutant p53. Both PUMA and NOXA
have been reported to be a direct transcriptional target of both
wild-type p53 and the transactivating isoforms of p63 and p73
(Oda et al, 2000; Melino et al, 2004; Flinterman et al, 2005).
Because mutant p53 has been hypothesised to function as an
inhibitor of its pro-apoptotic paralogues, TAp63 and TAp73
(Davison et al, 1999; Di Como et al, 1999; Marin et al, 2000; Strano
et al, 2000, 2002; Gaiddon et al, 2001), we investigated whether
induction of apoptosis after loss of mutant p53 was mediated by
TAp63 or TAp73. We inhibited TAp63 or TAp73 in T47D and
MDA-MB-468 cells by expressing a lentiviral shRNA construct that
we previously showed to be a potent and specific inhibitor of this
isoform, followed by a brief drug selection (Rocco et al, 2006; Leong
et al, 2007) (Figures 4B and C). Inhibition of TAp63 or TAp73 has
no effect on apoptosis induced by mutant p53 knockdown (Figures
4C and D). These data reveal that the apoptotic effects after RNAi
knockdown of mutant p53 in breast cancer cells are independent of
TAp63 or TAp73 function. Regardless of the mechanism involved,
it is likely that transcriptional dysregulation is the major factor
behind mutant p53 oncogenicity. Thus, identifying such new
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Figure 3 Rescue from apoptosis after reconstitution of siRNA-
insensitive mutant p53 R273H in MDA-MB-468 cells. (A) Apoptosis
induced by endogenous mutant p53 knockdown was completely rescued
after ectopic expression of siRNA-insensitive R273H p53 construct. MDA-
MB-468 cells were transfected with R273H p53 expression construct,
followed by a brief drug selection containing 500mgml
 1 G418
(Invitrogen). Cells were then transfected with an siRNA that targets
the 50-UTR of the endogenous mutant p53 (p53si-3). Western blot
analysis was performed 72h after transfection. (B) Quantitation of
apoptosis by annexin V/PI staining of cells was performed 96h after
mutant p53 knockdown. Error bars represent s.d. for three independent
experiments.
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Figure 4 Apoptosis induced by mutant p53 knockdown is independent of TAp63 or TAp73 function. (A) Knockdown of mutant p53 does not induce
the p53 pro-apoptotic targets, PUMA and NOXA, in T47D. T47D cells were harvested at different time points after p53 shRNA infection and were
analysed by immunoblotting with PUMA- and NOXA-specific antibodies. b-Tubulin served as loading control. (B) Specific and effective knockdown of
endogenous TAp63 and TAp73 in MDA-MB-468 cells. Pools of cells that stably express a TAp73-targeted shRNA (TAp73si) or TAp63-targeted shRNA
(TAp63si) were generated through infection of the respective shRNAs, followed by a brief drug selection. The expression level of TAp63 and TAp73 in the
stable cell line was evaluated by QRT-PCR. (C) Induction of apoptosis after mutant p53 knockdown is independent of TAp73 and TAp63 function in T47D
and MDA-MB-468 cells. TAp73- or TAp63-ablated cells were infected with p53-directed lentiviral shRNAs or controls, and lysates were harvested at 72h
for immunoblot. (D) Quantitation of apoptosis by annexin V/PI staining of cells 96h after mutant p53 knockdown. Error bars represent s.d. for three
independent experiments.
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spathways should provide attractive candidate prognostic markers
and therapeutic targets for refractory breast cancers, in which
mutant p53 has a prominent function.
DISCUSSION
p53 is arguably the most pivotal gene studied in the era of modern
molecular biology. The decision to repair or destroy the cell with
DNA damage is largely at the discretion of this major transcription
factor, which is important as a tumour suppressor (Selivanova,
2004). It has been reported by various studies that mutant p53 may
not only lose the tumour-suppressor functions of wild-type p53, or
have dominant-negative effect over endogenous wild-type p53, but
also acquire additional pro-oncogenic gain-of-function activities
(Sigal and Rotter, 2000; Zalcenstein et al, 2003). Indeed, several
studies, in both mice and humans, have shown an oncogenic
advantage for cells expressing mutant p53, in the absence of wild-
type p53 (Dittmer et al, 1993; Hsiao et al, 1994; Harvey et al, 1995;
Birch et al, 1998; Marutani et al, 1999; Liu et al, 2000). Several
biochemical and biological functions of mutant p53 proteins,
independent of the wild-type p53 protein, have also been
described. For instance, mutant p53 was shown to be an activator
of numerous genes, such as c-Myc, topoisomerase I, and MDR-1
(Murphy et al, 2000), to promote genomic instability and
disruption of spindle checkpoint control (Matas et al, 2001).
However, most of these studies reported thus far on the gain-of-
function activity of mutant p53 proteins have been performed on
an overexpression of exogenous mutant proteins. This artificial
system raised the question whether the pro-oncogenic effects of
mutant p53 observed in this system resemble the physiological
function of the endogenous mutant p53 in cancer cells (Vousden
and Prives, 2005, 2009). In this study, using an RNAi approach, we
studied the endogenous function of mutant p53 in a panel of breast
cancer cell lines that express only mutant p53. We show that p53
mutants exhibit gain-of-function activities in mediating cell
survival in breast cancer cells that expressed them. Silencing of
mutant p53 by lentiviral shRNA that targets specifically mutant
p53 in T47D and MDA-MB-468 cells induced massive apoptosis as
evidenced by morphological cell blebbing, PARP cleavage, and
annexin V/PI staining. These pro-apoptotic effects, however, were
not observed in MCF-7 or MCF-10A cells that express only wild-
type p53, nor were they observed in T47D or MDA-MB-468 cells
transduced with a non-targeting shRNA. Importantly, the apopto-
tic effects after mutant p53 knockdown were completely abrogated
in MDA-MB-468 cells reconstituted with an exogenous expression
of 50-UTR-deleted R273H mutant p53 after a knockdown of
endogenous mutant p53 using an siRNA that target the 50-UTR of
the endogenous mutant p53. These data provide strong evidence
that the pro-apoptotic effects we observed are mainly due to
the loss of mutant p53 function in these cells and not due to the
non-specific effects of the lentivirus.
Several models have been suggested to explain mutant p53 gain of
function. One proposes that mutant p53 directly regulates a specific
set of genes that mediate its oncogenic activities. A second model
proposes that some mutant forms of p53 acquire gain of function
through their interactions with the p53 family members, p63 and
p73 (Davison et al, 1999; Di Como et al,1 9 9 9 ;S t r a n oet al, 2000,
2002; Gaiddon et al, 2001). Both p63 and p73 share a structural
similarity with wild-type p53 (Kaelin, 1999; Yang et al,2 0 0 2 ;B e n a r d
et al, 2003). Overexpression of the transactivating isoforms of p73
and p63 (TAp73 and TAp63) has been shown to induce apoptosis
and transcriptional activation of genes containing a consensus p53-
DNA-binding sequence in their promoter region (Yang et al, 2002;
Davis et al, 2003). It has been observed that cell lines expressing
mutant p53 have a decreased sensitivity to chemotherapeutic agents,
and reports suggest that this is because of an interaction between
mutant p53 and endogenous TAp73 and/or TAp63 (Kaelin, 1999;
Gaiddon et al, 2001; Bensaad et al, 2003). Although there is sequence
similarity between the oligomerisation domains of p53, p73, and
p63, wild-type p53 does not hetero-oligomerise with p73 and p63
(Davison et al, 1999). More recent reports suggest that mutant p53
can interact with p73 and p63 by an association through the DNA-
binding domain of the mutant protein, thus inactivating p73 (and
p63) function (Strano et al, 2002; Bensaad et al,2 0 0 3 ) .
To test directly whether the apoptotic effects we observed after
knockdown of mutant p53 could be because of the loss of an
inhibitory effect of this protein towards TAp63 and/or TAp73, we
inhibited TAp63 or TAp73 in T47D and MDA-MB-468 cells by
expressing lentiviral shRNA constructs that have been previously
shown to be specific inhibitors of these isoforms, followed by a
brief drug selection (Rocco et al, 2006; Leong et al, 2007). Our
results show that the pro-apoptotic effect of mutant p53 knock-
down is independent of TAp63 or TAp73 function, as an ablation of
these two family members does not revert the apoptotic phenotype.
Because mutant p53 proteins are quite abundant in these
tumour cells, it is reasonable to speculate that they may physically
interact with many other proteins, or alternatively may function as
independent transcription factors to perform multiple functions.
Indeed, mutant p53 has been shown to function independently of
p63/p73 in other settings. For example, mutant p53 could interact
with NF-Y even in the presence of p63 and p73 to regulate a
distinct transcriptional programme as an oncogenic factor in
response to DNA damage (Di Agostino et al, 2006).
In conclusion, our results strongly suggest that mutant p53 has
an active function in mediating the survival of breast cancer cells.
These pro-survival effects of mutant p53 in T47D and MDA-MB-
468 are, however, unlikely to involve a functional interaction with
other p53 family members. The mechanism as to how mutant p53
exerts its pro-survival function in breast cancer cells remains to be
elucidated. Nevertheless, given the active function of mutant p53
proteins in promoting tumourigenesis and their very common
occurrence in breast cancer, the identification of pathways
regulated by distinct classes of mutant p53 proteins may provide
new therapeutic targets that would improve the treatment of
patients with refractory human breast cancers.
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